&lt;p&gt;Mesenchymal stem cell therapy assisted by nanotechnology: a possible combinational treatment for brain tumor and central nerve regeneration&lt;/p&gt;

Kwon, Soyoung; Yoo, Kwai Han; Sym, Sun Jin; Khang, Dongwoo

doi:10.2147/ijn.s217923

Cited by 41 publications

(31 citation statements)

References 184 publications

(218 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At these sites, the tumor oxidation state, vascularization and tumor inflammatory status can affect MSC migration efficiency ( 55 ). Furthermore, MSCs have been demonstrated to exert positive chemotactic effects on solid tumors, such as hepatocellular carcinoma ( 55 ), breast cancer ( 56 ) and glioma ( 57 ).…”

Section: Mscs Loaded With Ovs-the Anti-tumor Storymentioning

confidence: 99%

Mesenchymal stem cell carriers enhance anti‑tumor efficacy of oncolytic virotherapy (Review)

Zhao

2021

Oncol Lett

View full text Add to dashboard Cite

Oncolytic viruses (OVs) specifically infect, replicate and eventually destroy tumor cells, with no concomitant toxicity to adjacent normal cells. Furthermore, OVs can regulate tumor microenvironments and stimulate anti-tumor immune responses. Mesenchymal stem cells (MSCs) have inherent tumor tropisms and immunosuppressive functions. MSCs carrying OVs not only protect viruses from clearing by the immune system, but they also deliver the virus to tumor lesions. Equally, cytokines released by MSCs enhance anti-tumor immune responses, suggesting that MSCs carrying OVs may be considered as a promising strategy in enhancing the anti-tumor efficacies of virotherapy. In the present review, preclinical and clinical studies were evaluated and discussed, as well as the effectiveness of MSCs carrying OVs for tumor treatment.

show abstract

Section: Mscs Loaded With Ovs-the Anti-tumor Storymentioning

confidence: 99%

Mesenchymal stem cell carriers enhance anti‑tumor efficacy of oncolytic virotherapy (Review)

Zhao

2021

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Internalization/binding of drug-loaded nanoparticles into MSC can be exploited to increase the antitumor efficacy by targeted delivery to the tumour microenvironment. 120 Indeed, PTX loaded PLGA nanoparticles showed an enhanced activity in brain tumor, which is ascribed to the sustained release of the drug. 121 In a recent work, a hybrid system consisting of MSC spheroids and methotrexate (MTX)-loaded nanoparticles was engineered, in order to increase retention at tumour site: this system improved tumour inhibition in a heterotopic glioblastoma murine model.…”

Section: Nanocarrier-mediated Cell Therapymentioning

confidence: 99%

<p>Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours</p>

Ferraris¹,

Cavalli²,

Panciani³

et al. 2020

IJN

View full text Add to dashboard Cite

High-grade gliomas are still characterized by a poor prognosis, despite recent advances in surgical treatment. Chemotherapy is currently practiced after surgery, but its efficacy is limited by aspecific toxicity on healthy cells, tumour cell chemoresistance, poor selectivity, and especially by the blood-brain barrier (BBB). Thus, despite the large number of potential drug candidates, the choice of effective chemotherapeutics is still limited to few compounds. Malignant gliomas are characterized by high infiltration and neovascularization, and leaky BBB (the so-called blood-brain tumour barrier); surgical resection is often incomplete, leaving residual cells that are able to migrate and proliferate. Nanocarriers can favour delivery of chemotherapeutics to brain tumours owing to different strategies, including chemical stabilization of the drug in the bloodstream; passive targeting (because of the leaky vascularization at the tumour site); inhibition of drug efflux mechanisms in endothelial and cancer cells; and active targeting by exploiting carriers and receptors overexpressed at the blood-brain tumour barrier. Within this concern, a suitable nanomedicine-based therapy for gliomas should not be limited to cytotoxic agents, but also target the most important pathogenetic mechanisms, including cell differentiation pathways and angiogenesis. Moreover, the combinatorial approach of cell therapy plus nanomedicine strategies can open new therapeutical opportunities. The major part of attempted preclinical approaches on animal models involves active targeting with protein ligands, but, despite encouraging results, a few number of nanomedicines reached clinical trials, and most of them include drug-loaded nanocarriers free of targeting ligands, also because of safety and scalability concerns.

show abstract

“…The computational interpretation explains the interaction between nanodevices and cell/tissues exactly. [ 31 ]…”

Section: Concepts Of Convergence Of Nanotechnology and Stem Cell Therapymentioning

confidence: 99%

The convergence of nanotechnology‐stem cell, nanotopography‐mechanobiology, and biotic‐abiotic interfaces: Nanoscale tools for tackling the top killer, arteriosclerosis, strokes, and heart attacks

Kumar

Gulia

2020

Nano Select

View full text Add to dashboard Cite

The nanotechnology‐stem cell has enabled the engineering of nanotopographical surfaces for mimicking the topological features of nano‐stem cell interfaces and stem cell niches. The nanotechnology‐stem cell, an abiotic–biotic model, the impact of the multi‐functional materials underlying support on nanomaterials interactions with stem cells plays a significant role in the development of the nanoscale tools for tracking the top killer, arteriosclerosis, strokes, and heart attacks. The biomimetic topographical surfaces, employed in cell mechanobiology (cell adhesions, migrations, and differentiation) and tissue engineering. The conformational features of the scaffold (ridges, grooves, whorls, pits, and pores, and symmetry) alter stem cell behavior and differentiation. Biomedical engineering is offering promises and explaining how the convergence of nanotechnology and stem cells has emerged as novel therapeutics. The analysis of mechanotransduction and tissue engineering is the key factor, which altogether influence the stem cell niche, can be considered for originating nanno‐stem cell interface, and a useful remedy for treating cardiovascular diseases. The Hippo pathway underlined the signaling cascade responsible for inhibiting cell proliferation. Notch signaling is a key pathway that regulates the modulation of cardiomyocyte survival, cardiac stem cell differentiation. The Wnt/β‐catenin signaling involved in chronic infusion of angiotensin II (Ang II), cardiomyocytes, and cardiac fibroblasts.

show abstract

<p>Mesenchymal stem cell therapy assisted by nanotechnology: a possible combinational treatment for brain tumor and central nerve regeneration</p>

Cited by 41 publications

References 184 publications

Mesenchymal stem cell carriers enhance anti‑tumor efficacy of oncolytic virotherapy (Review)

Mesenchymal stem cell carriers enhance anti‑tumor efficacy of oncolytic virotherapy (Review)

<p>Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours</p>

The convergence of nanotechnology‐stem cell, nanotopography‐mechanobiology, and biotic‐abiotic interfaces: Nanoscale tools for tackling the top killer, arteriosclerosis, strokes, and heart attacks

Contact Info

Product

Resources

About